東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Preliminary Study: Leucine Supplemen...

Bejarano, Katarina.

FindBook

Google Book

Amazon

博客來

Preliminary Study: Leucine Supplementation Exacerbates Muscle Wasting Independent of the Ubiquitin-Proteasome System.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Preliminary Study: Leucine Supplementation Exacerbates Muscle Wasting Independent of the Ubiquitin-Proteasome System./
作者:	Bejarano, Katarina.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	74 p.
附註:	Source: Masters Abstracts International, Volume: 81-12.
Contained By:	Masters Abstracts International81-12.
標題:	Kinesiology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27960300
ISBN:	9798645461461

Preliminary Study: Leucine Supplementation Exacerbates Muscle Wasting Independent of the Ubiquitin-Proteasome System.
Bejarano, Katarina.

Preliminary Study: Leucine Supplementation Exacerbates Muscle Wasting Independent of the Ubiquitin-Proteasome System. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 74 p.

Source: Masters Abstracts International, Volume: 81-12.

Thesis (M.S.)--University of Arkansas, 2020.

This item must not be sold to any third party vendors.

Cancer cachexia is the rapid, drastic loss of muscle mass associated with cancer and is not reversible by conventional nutritional means (Brown et al., 2018; Brown et al., 2017). It occurs in ~80% of cancer patients and is responsible for 20-40% of cancer-related deaths (Brown et al., 2018; Brown et al., 2017). This condition leaves patients with fatigue, functional impairment, reduced quality of life, and a decrease in survival rates. Cachexia occurs through an imbalance between protein degradation and protein synthesis (Brown et al., 2018), which is associated with inflammation and altered metabolic processes.Several studies have investigated the effects of leucine on cancer cachexia, as it is known for promoting muscle growth through the stimulation of anabolic signaling cascades while inhibiting catabolism. These studies have all been conducted for a short period of time and have shown promise for leucine as a treatment for cancer cachexia. However, one study found that long-term (6 weeks) leucine supplementation increased epididymal fat mass while decreasing muscle mass in rats fed a high-fat diet (Baum et al., 2016). In addition, Lee et al. (2019) demonstrated exacerbated atrophy in tumor-bearing mice after 28 days of low-dose leucine supplementation. Whether leucine is a viable long-term treatment for cancer cachexia requires further investigation.10 C57BL/6 (WT) mice and 7 APCMin/+ (APC) mice were used in this study and given either tap water as a control or given 1.5% leucine-enriched water. Tissue harvest was conducted at ~24 weeks of age for genetic and western blot analysis. There was a main effect of genotype for decreased body and plantaris weight in APC mice compared to WT (p < 0.05), and a main effect of leucine for lower plantaris weight/tibia length in APC mice (p < 0.05), which appeared to be driven by the APCMin/+ genotype (p = 0.0841). Cyclin D1 mRNA abundance was ~2-fold greater in APC mice compared to WT, although no difference was found with treatment. No difference was found in MyoD or Myogenin mRNA abundance. Long-term leucine supplementation appears to exacerbate atrophy, which appeared to be independent of protein turnover or myogenesis disruption.

ISBN: 9798645461461Subjects--Topical Terms:

517627
Kinesiology.
Subjects--Index Terms:

APCMin/+

Preliminary Study: Leucine Supplementation Exacerbates Muscle Wasting Independent of the Ubiquitin-Proteasome System.
LDR:03290nmm a2200337 4500 001 2273994
005 20201109125405.5
008 220629s2020 ||||||||||||||||| ||eng d
020 $a 9798645461461
035 $a (MiAaPQ)AAI27960300
035 $a AAI27960300
040 $a MiAaPQ $c MiAaPQ
100 1 $a Bejarano, Katarina. $3 3551455
245 1 0 $a Preliminary Study: Leucine Supplementation Exacerbates Muscle Wasting Independent of the Ubiquitin-Proteasome System.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 74 p.
500 $a Source: Masters Abstracts International, Volume: 81-12.
500 $a Advisor: Washington, Tyrone A.
502 $a Thesis (M.S.)--University of Arkansas, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Cancer cachexia is the rapid, drastic loss of muscle mass associated with cancer and is not reversible by conventional nutritional means (Brown et al., 2018; Brown et al., 2017). It occurs in ~80% of cancer patients and is responsible for 20-40% of cancer-related deaths (Brown et al., 2018; Brown et al., 2017). This condition leaves patients with fatigue, functional impairment, reduced quality of life, and a decrease in survival rates. Cachexia occurs through an imbalance between protein degradation and protein synthesis (Brown et al., 2018), which is associated with inflammation and altered metabolic processes.Several studies have investigated the effects of leucine on cancer cachexia, as it is known for promoting muscle growth through the stimulation of anabolic signaling cascades while inhibiting catabolism. These studies have all been conducted for a short period of time and have shown promise for leucine as a treatment for cancer cachexia. However, one study found that long-term (6 weeks) leucine supplementation increased epididymal fat mass while decreasing muscle mass in rats fed a high-fat diet (Baum et al., 2016). In addition, Lee et al. (2019) demonstrated exacerbated atrophy in tumor-bearing mice after 28 days of low-dose leucine supplementation. Whether leucine is a viable long-term treatment for cancer cachexia requires further investigation.10 C57BL/6 (WT) mice and 7 APCMin/+ (APC) mice were used in this study and given either tap water as a control or given 1.5% leucine-enriched water. Tissue harvest was conducted at ~24 weeks of age for genetic and western blot analysis. There was a main effect of genotype for decreased body and plantaris weight in APC mice compared to WT (p < 0.05), and a main effect of leucine for lower plantaris weight/tibia length in APC mice (p < 0.05), which appeared to be driven by the APCMin/+ genotype (p = 0.0841). Cyclin D1 mRNA abundance was ~2-fold greater in APC mice compared to WT, although no difference was found with treatment. No difference was found in MyoD or Myogenin mRNA abundance. Long-term leucine supplementation appears to exacerbate atrophy, which appeared to be independent of protein turnover or myogenesis disruption.
590 $a School code: 0011.
650 4 $a Kinesiology. $3 517627
650 4 $a Physiology. $3 518431
653 $a APCMin/+
653 $a Cancer cachexia
653 $a Leucine
690 $a 0575
690 $a 0719
710 2 $a University of Arkansas. $b Kinesiology. $3 2102565
773 0 $t Masters Abstracts International $g 81-12.
790 $a 0011
791 $a M.S.
792 $a 2020
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27960300